NCT03203811View on ClinicalTrials.gov

A Phase 1, Study to Evaluate HTI-2088 Tablet

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 17, 2017

Primary Completion Date

October 23, 2017

Study Completion Date

October 23, 2017

Conditions
Diabetes
Interventions
DRUG

HTI-2088

3 dose levels

DRUG

Placebo

placebo oral tablet

Trial Locations (1)

45227

Medpace, Cincinnati

Sponsors
All Listed Sponsors
lead

Hengrui Therapeutics, Inc.

INDUSTRY